- Home
- NXPL vs CTXR Comparison
NXPL vs CTXR Comparison
Compare NXPL & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXPL | CTXR |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3M | 18.7M |
| IPO Year | 2011 | 2010 |
Fundamental Metrics
Financial Performance| Metric | NXPL | CTXR |
|---|---|---|
| Price | $7.01 | $0.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 28.4K | ★ 725.1K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.29 | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,869,558.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.50 | N/A |
| 52 Week Low | $0.34 | $0.47 |
| 52 Week High | $8.37 | $2.19 |
Technical Indicators
Market Signals| Indicator | NXPL | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 60.20 | 57.50 |
| Support Level | $5.54 | $0.64 |
| Resistance Level | $7.13 | $0.74 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 78.57 | 57.49 |
Price Performance
Historical ComparisonAbout NXPL NextPlat Corp
NextPlat Corp is an e-commerce and healthcare company. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.